BIGG

Directrices unificadas de la OMS sobre el tratamiento de la tuberculosis farmacorresistente

Organización Panamericana de la Salud.

Las cepas del bacilo tuberculoso con farmacorresistencia (TB-DR) son más difíciles de tratar que las farmacosensibles y amenazan el progreso mundial hacia los objetivos establecidos por la Estrategia Fin de la TB, de la Organización Mundial de la Salud (OMS). Por lo tanto, existe una necesidad imperio...

Tuberculosis/tratamiento farmacológico, Tuberculosis Resistente a Múltiples Medicamentos/prevención & control, Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico, Isoniazida/uso terapéutico, Política Informada por la Evidencia, Antirretrovirales/administración & dosificación, Tuberculosis/patología

Texto completo (enlace principal) Texto completo (enlace alternativo) Texto completo (enlace alternativo)

The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance

World Health Organization.

This document provides a summary of the evidence and recommendations for the use of SL-LPA for the detection of mutations associated with resistance to fluoroquinolones and SLID in patients with RR-TB and/or MDR-TB. The objectives of this policy guidance are to assess and compare the diagnostic accuracy ...

Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico, Antibióticos Antituberculosos/farmacología, Técnicas de Sonda Molecular, Pruebas de Sensibilidad Microbiana, Fluoroquinolonas/uso terapéutico, Farmacorresistencia Bacteriana/genética, Genotipo, Mutación, Tuberculosis Resistente a Múltiples Medicamentos/genética, Mycobacterium tuberculosis/efectos de los fármacos, Mycobacterium tuberculosis/genética

Texto completo

The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin

World Health Organization.

Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...

Técnicas de Sonda Molecular, Rifamicinas/uso terapéutico, Isoniazida/uso terapéutico, Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico, Antituberculosos/uso terapéutico, Isoniazida/farmacología, Rifampin/farmacología, Mycobacterium tuberculosis/efectos de los fármacos, Farmacorresistencia Bacteriana, Reproducibilidad de los Resultados

Texto completo

Systematic screening for active tuberculosis: principles and recommendations

World Health Organization.

WHO has developed guidelines on systematic screening for active tuberculosis (TB) based on a thorough review of available evidence. Early detection of TB is essential to further improve health outcomes for people with TB, and to reduce TB transmission more effectively. Systematic screening in high risk g...

Grupos de Riesgo, Algoritmos, Triaje/métodos, Trazado de Contacto, Tuberculosis/diagnóstico, Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico, Tamizaje Masivo/métodos

Texto completo (enlace principal) Texto completo (enlace alternativo)

Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update.

World Health Organization.

The global priorities for tuberculosis (TB) care and control are to improve case-detection and to detect cases earlier, including cases of smear-negative disease which are often associated with coinfection with the human immunodeficiency virus (HIV) and young age, and to enhance the capacity to diagnose ...

Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico, Tuberculosis/diagnóstico, Rifampin/farmacología, Mycobacterium tuberculosis/aislamiento & purificación, Infecciones por VIH/diagnóstico, Sensibilidad y Especificidad

Texto completo